Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 3/20 | 0.50 |
| ▸ | MMP9 | P14780 | 3/20 | 0.50 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP13 | P45452 | 2/20 | 0.50 |
| ▸ | MMP3 | P08254 | 1/20 | 0.50 |
| ▸ | MMP7 | P09237 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 3/20 | 0.47 |
| ▸ | MMP8 | P22894 | 1/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16232171 | 0.83 | PSEN1 (0.44) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL22206134 | 0.82 | CA1 (0.54) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL28230363 | 0.82 | CA1 (0.54) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL1200588 | 0.82 | CA1 (0.53) | MMP2MMP9MMP1MMP13MMP7 | |
| SCHEMBL8013573 | 0.81 | MMP2 (0.55) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL1464399 | 0.80 | MMP1 (0.54) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL1980896 | 0.80 | SLC1A3 (0.51) | MMP2MMP9MMP1MMP13MMP3 | |
| SCHEMBL6470795 | 0.79 | SLC1A3 (0.49) | CA1CA2SLC1A3SLC1A2SLC1A1 | |
| SCHEMBL23049688 | 0.78 | CA2 (0.48) | MMP2MMP9CA1CA2CA12 | |
| SCHEMBL23049767 | 0.78 | CA2 (0.48) | MMP2MMP9CA1CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-08-22 | — | — | US | disclosed |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2023-02-28 | — | — | US | disclosed |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-10-19 | — | — | US | disclosed |
| CN-107820425-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2021-08-31 | — | — | CN | disclosed |
| EP-3307262-B1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-05-19 | — | — | EP | disclosed |
| EP-3307262-B1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-05-19 | — | — | EP | disclosed |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | NMD PHARMA A/S (DK) | 2021-03-02 | — | — | US | disclosed |
| EP-3307262-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD Pharma ApS (DK) | 2018-04-18 | — | — | EP | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2018-04-12 | — | — | US | disclosed |
| CN-107820425-A | For treating the compound of neuromuscular disorder | NMD制药公司 | 2018-03-20 | — | — | CN | disclosed |
| WO-2016202341-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202341-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | NMD PHARMA APS (DK) | 2016-12-22 | — | — | WO | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | BIONOMICS LIMITED (AU) | 2015-10-22 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | MERCK PATENT GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11730714-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885 |
| US-10934244-B2 | Compounds for use in treating neuromuscular disorders | CPT1B, CLCN2, TNNC1 | MMP2 3144/4885MMP9 2977/4885MMP1 1299/4885 |
| US-20180099920-A1 | COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CPT1B, CLCN2, TNNC1 | MMP2 3144/4885MMP9 2977/4885MMP1 1299/4885 |
| US-11147788-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885 |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | MMP2 4169/4885MMP9 4343/4885MMP1 1205/4885 |
| US-11591284-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, CACNA1S | MMP2 4455/4885MMP9 4489/4885MMP1 929/4885 |
| US-20140336198-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | MMP2 4243/4885MMP9 2830/4885MMP1 3792/4885 |
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CLIC1, RYR2 | MMP2 4293/4885MMP9 4249/4885MMP1 1853/4885 |
| US-20150299184-A1 | Amine Derivatives as Potassium Channel Blockers | KCNA3, KCNH3, KCNK3 | MMP2 4243/4885MMP9 2830/4885MMP1 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.